Drug Regulator’s Announcement Affected Shares of Pfizer
The European Medicines Agency (EMA) is studying three new conditions reported by a small number of people after vaccination with Covid-19 shots from Pfizer and Moderna to assess if they may be possible side effects. Europe’s drug regulator’s announcement affected shares of Moderna, BioNTech, as well as Pfizer.
The agency is studying Erythema multiforme, a form of allergic skin reaction, and glomerulonephritis or kidney inflammation. It is also studying nephrotic syndrome, a renal disorder characterized by heavy urinary protein losses. The safety committee of the European Medicines Agency is studying three new conditions to learn more about possible side effects.
At the moment, Pfizer is the biggest supplier of Covid-19 vaccines in Europe. Medics administered more than 330 million doses of the Pfizer shot, Comirnaty. Pfizer developed Conirmary in cooperation with Germany’s BioNTech. BioNTech and its partner equally split expenses and profit from the Covid vaccine.
Its rival Moderna also sold millions of doses in Europe. More than 43.5 million doses of its vaccine, Spikevax, have been administered in the European Economic Area as of July 29.
Pfizer and its Covid-19 vaccine
In July, the European Medicines Agency found a possible link between very rare heart inflammation and the mRNA vaccines. The agency’s position echoes a similar conclusion reached by U.S. officials in June.
The EU’s drug regulator identified two side effects: myocarditis and pericarditis. The agency came to that conclusion after reviewing more than 300 cases of chest and heart inflammation among more than 190 million doses. The European regulator stressed that the benefits from these vaccines far outweigh any risks.
The agency also warned people about a side effect of another vaccine in July. People who have a history of a rare condition that causes blood vessels to leak should avoid the vaccine made by Johnson & Johnson. The EMA’s experts examined three cases of capillary leak syndrome in people who received the Johnson & Johnson vaccine.
On August 11, the European Medicines Agency stated that it requested more data from the companies. The agency disclosed new assessments as part of routine updates to the safety section of all authorized vaccines’ database. It also added menstrual disorders as a condition it was studying for vaccines, including those from AstraZeneca and Johnson & Johnson after the EMA’s update last week.
The post Drug Regulator’s Announcement Affected Shares of Pfizer appeared first on FinanceBrokerage.